Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 13, 2016. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific share allocation events within the GSK 401(K) plan.
Material Changes
On May 12, 2016, there were increases in the notional allocation of GSK American Depositary Shares (ADSs) following the revaluation of the cash element of the notional investment held within the GSK 401(K) plan. The transaction price was $42.07 per ADS.
- Dr M M Slaoui (Director): 18 ADSs
- Dr K Slaoui (Connected Person): 12 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Key Facts for Investor Verification
- Verify the impact of the 401(K) plan revaluation on director holdings.
- Confirm the transaction price of $42.07 per ADS as of May 12, 2016.
- Note that this filing does not contain financial performance data for the period.